Zantac Cancer Litigation: Federal Litigation Consolidation
Written By: Karen Im
In response to a growing number of digestive and blood cancer lawsuits surrounding popular heartburn drug Zantac nationwide, the U.S. Judicial Panel on Multidistrict Litigation (JPML) scheduled oral arguments to decide whether the allegations should be consolidated into coordinated pretrial proceedings before one judge.
“Zantac” is the popular brand name for the heartburn drug ranitidine, sold by companies such as Pfizer, GlaxoSmithKline, Sanofi, Boehringer, and more. This drug can be purchased over-the-counter or prescribed by a doctor.
After the FDA detected unacceptable levels of NDMA, a carcinogenic environmental contaminant, in several brand-name and generic heartburn medications in September, most Zantac products were pulled from the market. Major drug stores like CVS and Walgreens chose to no longer sell these medications.
Despite a number of pharmacies having followed in a voluntarily pulling of Zantac from their shelves, many are urging the FDA to initiate a nationwide Zantac recall.
FLOOD OF CLASS ACTION AND CANCER MASS TORT CLAIMS
In September 2019, around 15 class action and product liability lawsuits had already spanned across nine different federal court districts. The cases filed continue to increase in number by day, amalgamating thousands of claims nationwide under the Zantac litigation.
Since September, numerous recalls have been issued for different ranitidine products. In a hearing order issued on December 19, it was decided that the centralization of these cases would be considered on January 30 at the Sam M. Gibbons United States Courthouse in Tampa, Florida.
One of the more recent proposed class-action lawsuits were filed on January 2, accusing Pfizer of concealing knowledge of the carcinogenic nature of Zantac and omitting NDMA from its list of ingredients. Dana Viola, a New Jersey resident who took Zantac for 16 years until it began to be recalled by drugmakers, filed this lawsuit.
Pfizer replied to these allegations with a statement that it had not sold Zantac in 13 years. The New-York based drugmaker is planning to formally respond to the suit.
Do You have a Potential Zantac Cancer Lawsuit Which You Would Like Evaluated?
The attorneys at Rheingold Giuffra Ruffo & Plotkin LLP have successfully litigated dangerous drug cases against large pharmaceutical corporations for decades. We are currently speaking with individuals who may have developed cancer as a result of prolonged Zantac and ranitidine use. Please reach out to our law firm if you or a loved one developed cancer while taking Zantac. Our attorneys will schedule an appointment to speak with you about your specific case and needs. You can reach our New York office location by calling (888) 260-0473. Communications with our firm are strictly confidential, and we can help you understand whether or not you have a strong Zantac lawsuit. The consultation is free of charge and we do not charge you for litigating your case. Additionally, our firm will get a fee only if we recover a settlement for you.